Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810122 | 0.87 | BRD4 (0.44) | NR1I2BRD4KDM4ECCR2 | |
| SCHEMBL3910618 | 0.83 | SGK1 (0.41) | NR1I2PTGDR2BRD4HTR6 | |
| SCHEMBL1811855 | 0.83 | PKM (0.40) | NR1I2PTGDR2BRD4HTR6 | |
| SCHEMBL3908715 | 0.83 | ITGA1 (0.51) | NR1I2PTGDR2BRD4SERPINE1 | |
| SCHEMBL1814225 | 0.82 | PTGDR2 (0.46) | NR1I2PTGDR2FABP4FABP5BRD4 | |
| SCHEMBL4536214 | 0.82 | NR1I2 (0.52) | NR1I2BRD4HTR6 | |
| SCHEMBL3906718 | 0.82 | SLC22A12 (0.50) | NR1I2BRD4 | |
| SCHEMBL3915102 | 0.81 | PTGDR2 (0.48) | NR1I2PTGDR2BRD4SERPINE1 | |
| SCHEMBL3903016 | 0.79 | NR1I2 (0.48) | NR1I2BRD4 | |
| SCHEMBL3906967 | 0.79 | PKM (0.40) | NR1I2PTGDR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4682207-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | claimed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | claimed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | NR1I2 79/4885PTGDR2 925/4885FABP4 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.